ICON Public (NASDAQ:ICLR) Given New $275.00 Price Target at Barclays

ICON Public (NASDAQ:ICLR) had its target price decreased by research analysts at Barclays from $330.00 to $275.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective suggests a potential upside of 24.51% from the company’s previous close.

ICLR has been the topic of several other reports. Redburn Atlantic began coverage on shares of ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price objective on the stock. Robert W. Baird lowered shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price objective on the stock. in a report on Thursday. Evercore ISI dropped their target price on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Truist Financial decreased their price target on ICON Public from $383.00 to $363.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. Finally, Leerink Partnrs upgraded ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ICON Public presently has a consensus rating of “Moderate Buy” and a consensus price target of $318.45.

ICON Public Trading Down 0.4 %

Shares of ICLR traded down $0.86 during mid-day trading on Friday, reaching $220.87. The stock had a trading volume of 1,634,592 shares, compared to its average volume of 616,444. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The business’s fifty day moving average is $299.79 and its 200 day moving average is $310.96. ICON Public has a 52-week low of $220.51 and a 52-week high of $347.72. The firm has a market cap of $18.22 billion, a price-to-earnings ratio of 26.88, a P/E/G ratio of 1.35 and a beta of 1.22.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.10 EPS. On average, sell-side analysts predict that ICON Public will post 14.54 EPS for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Several institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its stake in ICON Public by 17.4% during the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after purchasing an additional 42 shares during the last quarter. Motco raised its holdings in ICON Public by 1.5% during the first quarter. Motco now owns 3,882 shares of the medical research company’s stock worth $1,304,000 after purchasing an additional 59 shares in the last quarter. First National Bank of Hutchinson lifted its position in shares of ICON Public by 5.7% during the 1st quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock worth $381,000 after buying an additional 61 shares during the last quarter. Arkadios Wealth Advisors boosted its holdings in shares of ICON Public by 5.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after buying an additional 62 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of ICON Public by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after buying an additional 87 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.